Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups (This dataset does not contain this module)
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE131984_Pac

Dataset summary for GSE131984_Pac

Datast information	Dataset	GSE131984_Pac
	PMID	32393766
	Raw data ID/link	PRJNA545508
	Organism	Homo sapiens
	Source	SUM159 cell line
	Tissue	Cell line
	Cancer type level1	Breast cancer
	Cancer type level2	Triple-negative breast cancer (TNBC)
	Regimen	paclitaxel
	Drug type	Chemotherapy
	Sample size	resistant 1, sensitive 2
	Cell number	1813
	Extract protocol	10x genomics
	Data processing	CellRanger 2.1.0
	Public date	Public on Apr 08, 2020
	Description	This dataset has 1 cell line with 2 sensitive pre-treatment samples and 1 resistant post-treatment sample.

Top

Drug summary for GSE131984_Pac

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"Paclitaxel"	DB01229	small molecule	TUBB1; BCL2; MAP4; MAP2; MAPT; NR1I2	Q9H4B7; P10415; P27816; P11137; P10636; O75469

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types	Umap of conditions
Umap of cell clusters	Cell ratio of drug-resistant and sensitive groups within each cluster

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
ODC1	ENSG00000115758	1.04603	0.00e+00	0.00e+00	1	0.993	Malignant cells	NA
TOMM40	ENSG00000130204	0.904662	0.00e+00	0.00e+00	0.999	0.977	Malignant cells	NA
LINC00958	ENSG00000251381	0.888021	0.00e+00	0.00e+00	0.888	0.648	Malignant cells	NA
SRM	ENSG00000116649	0.824301	0.00e+00	0.00e+00	1	0.997	Malignant cells	NA
LYAR	ENSG00000145220	0.804521	0.00e+00	0.00e+00	0.948	0.814	Malignant cells	NA
GPATCH4	ENSG00000160818	0.782506	0.00e+00	0.00e+00	0.969	0.853	Malignant cells	NA
FABP5	ENSG00000164687	0.774992	0.00e+00	0.00e+00	0.999	0.993	Malignant cells	NA
CCND1	ENSG00000110092	0.753783	0.00e+00	0.00e+00	0.989	0.943	Malignant cells	NA
KRT7	ENSG00000135480	0.716414	0.00e+00	0.00e+00	1	0.999	Malignant cells	NA
DKC1	ENSG00000130826	0.716266	0.00e+00	0.00e+00	0.969	0.861	Malignant cells	NA
ATAD3B	ENSG00000160072	0.699279	0.00e+00	0.00e+00	0.731	0.378	Malignant cells	NA
SCG5	ENSG00000277614	0.693042	5.18e-44	7.89e-40	0.875	0.633	Malignant cells	NA
NOP56	ENSG00000101361	0.667169	0.00e+00	0.00e+00	0.984	0.919	Malignant cells	NA
SURF2	ENSG00000281024	0.666424	0.00e+00	0.00e+00	0.908	0.704	Malignant cells	NA
POLR3H	ENSG00000100413	0.664447	0.00e+00	0.00e+00	0.931	0.747	Malignant cells	NA
POLR3K	ENSG00000161980	0.661588	0.00e+00	0.00e+00	0.96	0.834	Malignant cells	NA
FAM58A	NA	0.660025	0.00e+00	0.00e+00	0.957	0.81	Malignant cells	NA
TIMP1	ENSG00000102265	0.655753	2.09e-26	3.23e-22	1	1	Malignant cells	NA
UBE2S	ENSG00000108106	0.649315	0.00e+00	0.00e+00	1	0.999	Malignant cells	NA
NCL	ENSG00000115053	0.647688	0.00e+00	0.00e+00	1	0.992	Malignant cells	NA
HSPA8	ENSG00000109971	0.644944	8.41e-45	1.20e-40	0.999	0.999	Malignant cells	NA
RPS19BP1	ENSG00000187051	0.641902	0.00e+00	0.00e+00	0.999	0.982	Malignant cells	NA
CD59	ENSG00000085063	0.63905	0.00e+00	0.00e+00	0.996	0.979	Malignant cells	NA
MRPS12	ENSG00000283018	0.629705	0.00e+00	0.00e+00	0.997	0.971	Malignant cells	NA
NOP16	ENSG00000048162	0.615534	0.00e+00	0.00e+00	0.96	0.867	Malignant cells	NA
C11orf48	NA	0.614	0.00e+00	0.00e+00	0.995	0.949	Malignant cells	NA
UBE2C	ENSG00000175063	0.596343	1.42e-18	2.20e-14	0.838	0.685	Malignant cells	NA
EMC6	ENSG00000127774	0.595873	0.00e+00	0.00e+00	0.995	0.962	Malignant cells	NA
C1QBP	ENSG00000108561	0.587547	0.00e+00	0.00e+00	1	0.996	Malignant cells	NA
HNRNPAB	ENSG00000197451	0.587088	0.00e+00	0.00e+00	0.997	0.973	Malignant cells	NA
RPUSD1	ENSG00000007376	0.586858	0.00e+00	6.24e-42	0.839	0.611	Malignant cells	NA
DNAJC9	ENSG00000213551	0.584949	0.00e+00	1.26e-44	0.92	0.777	Malignant cells	NA
CDC20	ENSG00000117399	0.584559	5.60e-39	8.63e-35	0.944	0.812	Malignant cells	NA
DKK1	ENSG00000107984	0.580968	7.22e-21	1.11e-16	0.818	0.676	Malignant cells	NA
ZNF593	ENSG00000142684	0.574718	0.00e+00	0.00e+00	0.979	0.912	Malignant cells	NA
CD3EAP	NA	0.574176	2.40e-40	3.69e-36	0.672	0.415	Malignant cells	NA
POP7	ENSG00000172336	0.568255	0.00e+00	0.00e+00	0.993	0.933	Malignant cells	NA
LSM10	ENSG00000181817	0.567703	0.00e+00	0.00e+00	0.979	0.888	Malignant cells	NA
MARCKSL1	ENSG00000175130	0.567412	1.60e-30	2.46e-26	0.694	0.469	Malignant cells	NA
RANBP1	ENSG00000099901	0.563765	0.00e+00	0.00e+00	1	0.996	Malignant cells	NA
CCDC86	ENSG00000110104	0.563448	2.80e-45	3.72e-41	0.746	0.47	Malignant cells	NA
POLE3	ENSG00000148229	0.563155	0.00e+00	6.10e-42	0.878	0.713	Malignant cells	NA
EBNA1BP2	ENSG00000117395	0.548813	0.00e+00	0.00e+00	0.997	0.987	Malignant cells	NA
YDJC	ENSG00000161179	0.533869	6.16e-42	9.49e-38	0.892	0.756	Malignant cells	NA
DDX21	ENSG00000165732	0.531501	0.00e+00	0.00e+00	0.999	0.983	Malignant cells	NA
NAA10	ENSG00000102030	0.526945	0.00e+00	0.00e+00	1	1	Malignant cells	NA
MRPL20	ENSG00000242485	0.52549	0.00e+00	0.00e+00	1	0.996	Malignant cells	NA
IGFBP4	ENSG00000141753	0.521299	5.10e-18	7.86e-14	0.882	0.861	Malignant cells	NA
RRP9	ENSG00000114767	0.521009	1.24e-35	1.92e-31	0.664	0.42	Malignant cells	NA
NIFK	ENSG00000155438	0.518374	1.21e-33	1.87e-29	0.843	0.686	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	1.10e-09	5.50e-09	870	781	65	23467	Malignant cells	AURKA,BBC3,BIRC5,CDK4,CFLAR,DNMT1,FADD,HMGA1,ID1,IFI27,IL6,ISG15,JUN,MAP1LC3B,PDGFRA,S100A4,STMN1,TIMP3,SLC25A5,ANXA1,BAG1,BTG1,CCND1,CCNG1,HSPD1,COL1A1,DKK1,DUSP1,EGR1,EIF3A,FUS,HNRNPU,HSPA8,HSPB1,IDH1,EIF4E,NFKBIA,IL18,LAMP2,MTDH,MAP3K8,MXD4,NF2,MYO10,PLK1,HRAS,RRM2,S100A11,SFPQ,SMC4,SOD2,TFAM,TMED3,TNFAIP3,TOP1,UBE2C,FASN,CEBPD,IDI1,INSIG1,SPHK1,SAFB2,EBP,NUPR1,ACAT2
Irregularity in Drug Uptake and Drug Efflux	4.70e-02	1.20e-01	870	37	4	23467	Malignant cells	ABCF2,ABCE1,SLC7A5,SLC29A1
Drug Inactivation by Structure Modification	7.70e-02	1.30e-01	870	27	3	23467	Malignant cells	SOD2,CDA,NME1
Aberration of the Drug's Therapeutic Target	2.40e-01	3.00e-01	870	90	5	23467	Malignant cells	CDK4,PDGFRA,IDH1,MAOA,AKR1B1
Epigenetic Alteration of DNA, RNA or Protein	9.50e-01	9.50e-01	870	455	11	23467	Malignant cells	DNMT1,EIF4G2,IL6,PMAIP1,IDH1,MAP3K8,SMC4,TIMP1,MALAT1,PPP1R15A,DLEU1

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	5.52	0.0588	ETS2 (directAnnotation).	Malignant cells
	metacluster_34.4	5.39	0.0579	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	4.83	0.0541	ELF1; MEIS1 (directAnnotation).	Malignant cells
	metacluster_166.2	4.46	0.0516	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_191.3	4.26	0.0503	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).	Malignant cells
	metacluster_34.3	4.24	0.0501	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).	Malignant cells
	metacluster_191.2	4.2	0.0499	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	jaspar__MA1483.2	4.02	0.0486	ELF2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	3.92	0.0479	ETV5; HOXA2 (directAnnotation).	Malignant cells
	metacluster_166.4	3.88	0.0477	BCLAF1; EHF; ELF1; ELF1; ELF1; ELF1; ELF1; ELF1; ELF2; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK1; ELK3; ELK3; ELK3; ELK3; ELK4; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS1; ETS1; ETS1; ETV1; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV4; ETV4; ETV4; ETV4; ETV5; ETV7; FEV; FEV; FLI1; FLI1; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; GABPB1; GATAD1; PHF20; ZBTB25; ZBTB40 (directAnnotation). EHF; ELF1; ELF1; ELF3; ELF5; ELK3; ELK4; ERG; ETS1; ETV1; ETV2; ETV4; FLI1; GABPA; GABPA (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	metacluster_22.29	5.25	0.0693	NFE2 (directAnnotation).	Malignant cells
	metacluster_174.3	5.14	0.0685	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).	Malignant cells
	metacluster_22.25	4.84	0.066	NFE2L2 (directAnnotation).	Malignant cells
	metacluster_2.7	4.81	0.0658	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).	Malignant cells
	metacluster_22.12	4.66	0.0645	NFE2; NFE2L1 (directAnnotation).	Malignant cells
	jaspar__MA0502.2	4.51	0.0633	NFYB (directAnnotation).	Malignant cells
	metacluster_22.18	4.49	0.0632	BACH2 (inferredBy_Orthology).	Malignant cells
	jaspar__MA0604.1	4.46	0.063	ATF1 (inferredBy_Orthology).	Malignant cells
	homer__GGAAATTCCC_NFkB-p65-Rel	4.45	0.0629	RELA (inferredBy_Orthology).	Malignant cells
	metacluster_22.32	4.41	0.0626	NFE2L2 (directAnnotation).	Malignant cells

Page: 1 2 3 4 5

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
CEBPZ	metacluster_174.2	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_HOXA13_GGWATGNNNRTAAA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_DRGX_GGAATGTTAATTR_CAP	up	Malignant cells	NA
FOSL1	metacluster_137.2	up	Malignant cells	NA
PITX1	taipale_tf_pairs__TEAD4_PITX1_RCATWCNNNNNGGATTA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_PITX1_RCATWCNNNNNGGATTA_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_HOXB13_GGWATGNNNRTAAA_CAP	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP_repr	up	Malignant cells	NA
TEAD4	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."